Rodin Therapeutics Obtains $17,300,000 New Financing

  • Feed Type
  • Date
    1/6/2016
  • Company Name
    Rodin Therapeutics
  • Mailing Address
    400 Technology Square Cambridge, MA 02139 USA
  • Company Description
    Rodin is harnessing the power of epigenetic regulation of neuronal function to treat diseases of the brain. We believe modulation of selective epigenetic regulatory processes can restore synaptic plasticity and cognitive function in degenerative brain diseases, as well as to aid the brain in reducing negative associations with traumatic memories.
  • Website
    http://www.rodintherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $17,300,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The Biogen investment and collaboration is a strong validation of our efforts to become the leader in targeted HDAC2 inhibition, and we look forward to working closely with Biogen to advance Rodin’s novel science. Rodin and Biogen have entered into a multi-year research collaboration around neuronal epigenetics.
  • M&A Terms
  • Venture Investor
    Accomplice
  • Venture Investor
    Biogen Idec

Trending on Xconomy